Lupin Ltd (LUPN.NS) Quote| Reuters.com
Edition:
United States

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,539.70INR
30 Jun 2016
Change (% chg)

Rs6.80 (+0.44%)
Prev Close
Rs1,532.90
Open
Rs1,548.00
Day's High
Rs1,554.00
Day's Low
Rs1,532.00
Volume
1,024,791
Avg. Vol
1,837,691
52-wk High
Rs2,129.00
52-wk Low
Rs1,280.00

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is an India-based transnational pharmaceutical company. The Company is engaged in the producing, developing and marketing of branded and generic formulations, and active pharmaceutical ingredients (APIs). The Company's brands include Gluconorm, Tonact, Rablet, Budamate, Telekast, Rcinex, Clopitab, Telista, Ramistar... (more)

Overall

Beta: 0.02
Market Cap(Mil.): Rs691,159.12
Shares Outstanding(Mil.): 450.88
Dividend: 7.50
Yield (%): 0.49

Financials

  LUPN.NS Industry Sector
P/E (TTM): 30.57 34.76 35.71
EPS (TTM): 50.15 -- --
ROI: 17.27 15.00 14.23
ROE: 22.87 16.06 15.43

Morning News Call - India, May 20

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_05202016.pdf FACTORS TO WATCH 10:00 am: Banks Board Bureau Chairman Vinod Rai at CII Banking and Finance summit in New Delhi. 10:30 am: Exim Bank Chairman Yaduvendra Mathur at media conference to release annual results in Mumbai. 2:30 pm: Foreign Investment Promotion Board meets to consider 14 FDI proposals in New Delhi. 3:00 pm: IDBI Bank Chief Executive Kis

May 19 2016

UPDATE 1-India's Lupin Q4 profit beats estimates as U.S. sales jump

* Q4 profit 8.07 bln rupees vs 6.78 bln rupees analysts expected

May 19 2016

BRIEF-Lupin CEO says to focus on growing specialty business on the acquisitions front

* CEO Vinita Gupta says on the acquisitions front, focus will be to grow specialty business

May 19 2016

India's Lupin Q4 profit up 48 pct, beats estimates

MUMBAI, May 19 Lupin Ltd, India's third-largest drugmaker, reported a 48 percent rise in quarterly net profit, outpacing analysts' estimates mainly due to higher drug sales in its largest market, the United States.

May 19 2016

India's Lupin says it sees no supply disruption at plant despite FDA observations

MUMBAI Lupin Ltd, India's third-largest drugmaker, said on Tuesday it did not expect any disruption to supply from its main manufacturing plant despite what it called minor observations made by the U.S. Food and Drug Administration after an audit.

Mar 29 2016

Indian shares bounce back to close higher; Fed eyed

March 16 Indian shares clawed back losses to close higher on Wednesday, led by gains in beaten-down healthcare stocks such as Lupin and as a rise in crude oil prices propped up global markets.

Mar 16 2016

Morning News Call - India, February 22

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_02222016.pdf FACTORS TO WATCH 5:00 pm: DIPP Secretary Amitabh Kant at an awards event in New Delhi. EMEA LIVECHAT- FX WEEK AHEAD with Reuters FX analyst Jeremy Boulton- Join Reuters FX analyst Jeremy Boulton at 1530 IST for a look at the week's top topics and implications for the FX market. To join the Global Markets Forum, click on the link: https://forms.t

Feb 21 2016

Lupin to divest two Gavis drugs for deal approval - FTC

Lupin Ltd will divest two generic drugs sold by Gavis Pharmaceuticals LLC to clear antitrust hurdles related to its $880 million acquisition of the company, the U.S. Federal Trade Commission said on Friday.

Feb 19 2016

Lupin to divest two Gavis drugs for deal approval - FTC

India's Lupin Ltd will divest two generic drugs sold by Gavis Pharmaceuticals LLC to clear antitrust hurdles related to its $880 million acquisition of the company, the U.S. Federal Trade Commission said on Friday.

Feb 19 2016

Lupin to divest two Gavis drugs for deal approval: FTC

India's Lupin Ltd will divest two generic drugs sold by Gavis Pharmaceuticals LLC to clear antitrust hurdles related to its $880 million acquisition of the company, the U.S. Federal Trade Commission said on Friday.

Feb 19 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Kisan Ratilal Choksey Shares and Securities Private Limited
$81.00
Provider : Wright Reports
$75.00
Provider : Motilal Oswal Securities Ltd.
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.